Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily pill help restore skin color in vitiligo?

NCT ID NCT06072183

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 study tests ritlecitinib, an oral drug, in adults with nonsegmental vitiligo, a condition causing white patches on the skin. About 1,571 participants will receive either 50 mg, 100 mg of ritlecitinib, or a placebo daily for up to 104 weeks. The goal is to see if the drug can safely reduce the size of white patches by at least 75% on the face and 50% on the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ritlecitinib
What this could lead to
If successful, this could lead to the first approved oral treatment for nonsegmental vitiligo, helping to restore skin color in affected areas.
What could go wrong
This is a Phase 3 trial, but results are not yet available. The drug may not work for everyone, and side effects are possible. It is also not a cure, as ongoing treatment may be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,571 people

The number who actually took part.

Started

Nov 2023

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants aged 18 years (or the minimum age of consent in accordance with local regulations) or older (no upper age limit) at Screening. • Meeting reproductive criteria for female participants. Disease Characteristics: 2. Eligible participants must have at both Screening and BL: * A clinical diagnosis of nonsegmental vitiligo for at least 3 months; and * BSA involvement 4% to 60% inclusive, excluding involvements at palms of the hands, soles of the feet, or dorsal aspect of the feet and * BSA ≥0.5% involvement on the face. Face is defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. Face will not include scalp, ears, neck, or surface area of the lips, but will include the nose and the eyelids; and * F-VASI ≥0.5 and T-VASI ≥3; and * Either active or stable nonsegmental vitiligo at Screening and BL visits. All participants who do not have the features of active vitiligo (defined below) will be classified as having stable disease. Active vitiligo is defined as: Participants will be classified as having active vitiligo based on the presence of at least one active lesion at BL defined as one of the following: * New/extending lesions(s) in the 3 months prior to Screening visit (confirmed by photographs or medical record); * Confetti-like lesion(s); Confetti-like depigmentation is characterized by the presence of numerous 1-mm to 5-mm depigmented macules in clusters; * Trichrome lesion(s); Trichrome lesions have a hypopigmented zone of varying width between normal and completely depigmented skin, resulting in 3 different hues of skin; * Koebner phenomenon/phenomena (excluding Type 1 \[history based on isomorphic reaction\]). The Koebner phenomenon manifests as depigmentation at sites of trauma, usually in a linear arrangement. Stable vitiligo is defined as: • Participants will be classified as having stable vitiligo based on an absence of signs of active disease. All participants who do not have the features of active vitiligo (defined above) will be classified as having stable disease. Eligibility is determined at Screening and Baseline based on the resulting scores from the local in-person reads of F-VASI, T-VASI, and BSA. 3. Additional inclusion criteria are: * If receiving concomitant medications for any reason other than vitiligo, participant must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to Day 1. Participant must be willing to stay on a stable regimen during the duration of the study. * Must agree to stop all other treatments for vitiligo from Screening through the final follow-up visit. Exclusion Criteria: Medical Conditions: 1. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. • Any psychiatric condition including recent or active suicidal ideation or behavior that meets defined criteria. 2. Medical conditions pertaining to vitiligo and other diseases/conditions affecting the skin: * Participants that have other types of vitiligo that do not meet criteria for active or stable vitiligo as noted in inclusion criteria (including but not limited to segmental vitiligo and mixed vitiligo). * Currently have active forms of other hypopigmentation (including but not limited to Vogt-Koyanagi-Harada disease, malignancy-induced hypopigmentation \[melanoma and mycosis fungoides\], post-inflammatory hypopigmentation, pityriasis alba \[minor manifestation of atopic dermatitis\], senile leukoderma \[age-related depigmentation\], chemical/drug-induced leukoderma, ataxia telangiectasia, tuberous sclerosis, melasma, and congenital hypopigmentation disorder including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, dyschromatosis symmetrica hereditarian, xeroderma pigmentosum, and nevus depigmentosus). NOTE: Coexistence of halo nevus/nevi (also known as Sutton nevus/nevi) is permitted. * Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions (for example, but not limited to morphea, discoid lupus, leprosy, syphilis, psoriasis, seborrheic dermatitis) at the time of the Screening or BL Visit that in the opinion of the investigator would interfere with evaluation of vitiligo or response to treatment. * Leukotrichia in more than 33% of the face surface area affected with vitiligo lesions or leukotrichia in more than 33% of the total body surface area affected with vitiligo lesions. * Have a superficial skin infection within 2 weeks prior to first dose on Day 1. NOTE: participants may be rescreened after the infection resolves. 3. General Infection History: * Have a history of systemic infection requiring hospitalization, parenteral antimicrobial, antiviral (including biologic treatment), antiparasitic, antiprotozoal, or antifungal therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 1. * Have active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 1. NOTE: participants may be rescreened after the infection resolves. * Evidence or history of untreated, currently treated or inadequately treated active or latent infection with Mycobacterium tuberculosis. 4. Specific Viral Infection History: * History (single episode) of disseminated HZ or disseminated herpes simplex or recurrent (more than one episode of) localized, dermatomal HZ. * Infected with HBV or HCV: all participants will undergo screening for HBV and HBC for eligibility. * Participants who are positive for HCVAb and HCV RNA will not be eligible for this study. * Have a known immunodeficiency disorder (including positive serology for HIV at screening) or a first-degree relative with a hereditary immunodeficiency. 5. Other Medical Conditions: * Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (eg, untreated hypovitaminosis D or hypothyroidism), pulmonary, cardiovascular, psychiatric, immunologic/rheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator or Pfizer (or designee), the participant is inappropriate for entry into this study, or unwilling/unable to comply with study procedures and lifestyle requirements. * History of severe allergic or anaphylactoid reaction to any kinase inhibitor or a known allergy/hypersensitivity to any component (including excipients) of the study intervention. * Have hearing loss with progression over the previous 5 years, sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered current, fluctuating, or progressive. * Have a history of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease. * Abnormal findings on the Screening chest imaging (eg, chest x-ray). Chest imaging may be performed up to 12 weeks prior to screening. Documentation of the official reading must be located and available in the source documentation. * Long QT Syndrome, a family history of Long QT Syndrome, or a history of TdP. * Have any malignancies or have a history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ. * Significant trauma or major surgery within 1 month of the first dose of study drug or considered in imminent need for surgery or with elective surgery scheduled to occur during the study. Prior/Concomitant Therapy: 6. Have received any of the prohibited treatment regimens specified. Prior/Concurrent Clinical Study Experience: 7. Previous administration with an investigational drug or vaccine that do not affect vitiligo within 4 weeks of Day 1 \[Baseline\] or within 5 half-lives, whichever is longer. Diagnostic Assessments: Any of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study-specific laboratory and, if deemed necessary, confirmed by a single repeat: 8. Renal impairment 9. Hepatic dysfunction 10. Other laboratory abnormalities 11. Standard 12-lead ECG that demonstrates clinically relevant abnormalities Other Exclusion Criteria: 12. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Active nonsegmental vitiligo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Active nonsegmental vitiligo Stable nonsegmental vitiligo

Contacts and locations

Locations

  • "DERMED" Centrum Medyczne Sp. z o.o.

    Lodz, Łódź Voivodeship, 90-265, Poland

  • "Diagnostic - Consultative Center XX - Sofia" EOOD

    Sofia, 1618, Bulgaria

  • ASL1 Avezzano-Sulmona-L'Aquila

    L’Aquila, Abruzzo, 67100, Italy

  • ASMC - IPSMC - skin and venereal diseases

    Sofia, Sofia (stolitsa), 1407, Bulgaria

  • AUDIKA

    Córdoba, Andalusia, 14001, Spain

  • Advanced Clinical Research Institute

    Tampa, Florida, 33607, United States

  • Alberta Dermasurgery Centre

    Edmonton, Alberta, T6G 1C3, Canada

  • Alpha Recherche Clinique

    Québec, G2J 0C4, Canada

  • Arké SMO S.A de C.V

    Veracruz, 91900, Mexico

  • Austin Institute for Clinical Research

    Pflugerville, Texas, 78660, United States

  • BAG Drs. Med. Quist PartG

    Mainz, Rhineland-Palatinate, 55128, Germany

  • Beijing Friendship Hospital Affiliate of Capital University

    Beijing, Beijing Municipality, 100050, China

  • BeneDerma

    Bratislava, 841 02, Slovakia

  • Bexley Dermatology Research

    Bexley, Ohio, 43209, United States

  • Bezmialem Vakf Üniversitesi

    Istanbul, 34093, Turkey (Türkiye)

  • Bio-Medical Research LLC

    Miami, Florida, 33144, United States

  • CLINIQ s.r.o.

    Bratislava, 811 09, Slovakia

  • CS Mott Center

    Detroit, Michigan, 48201, United States

  • Cardiovascular Radiology Institute

    San Juan, 00909, Puerto Rico

  • Center for Clinical Studies

    Houston, Texas, 77004, United States

  • Center for Dermatology and Plastic Surgery/CCT Research

    Scottsdale, Arizona, 85260, United States

  • Center for Skin and Venereal Diseases - Veliko Tarnovo

    Veliko Tarnovo, 5000, Bulgaria

  • Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman

    Liège, 4000, Belgium

  • Centre de Recherche Dermatologique du Quebec metropolitain

    Québec, G1V 4X7, Canada

  • Centre de Recherche Saint-Louis

    Montreal, Quebec, H1Y 3L1, Canada

  • Centre de Recherche Saint-Louis

    Sherbrooke, Quebec, J1G 1X9, Canada

  • Centricity Research Columbus Ohio Multispecialty

    Columbus, Ohio, 43213, United States

  • Centro de Audiología y Balance

    San Juan, 00927, Puerto Rico

  • Centrum Medyczne Angelius Provita

    Katowice, Silesian Voivodeship, 40-611, Poland

  • Chang Gung Medical Foundation-Linkou Branch

    Taoyuan, 333, Taiwan

  • Chengdu second people's hospital

    Chengdu, Sichuan, 610017, China

  • Clever Medical Research

    Miami, Florida, 33126, United States

  • Clinic EvroDerma

    Sofia, Sofia (stolitsa), 1606, Bulgaria

  • ClinicMed Daniluk, Nowak Spółka komandytowa

    Bialystok, Podlaskie Voivodeship, 15-879, Poland

  • Clinica Dermatoestetica Prywatny Gabinet Dermatologiczny I Alergologiczny Prof.Dr Hab.Med. Barbara Z

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-650, Poland

  • Clinica Universidad de Navarra

    Madrid, 28027, Spain

  • Clinica de Enfermedades Cronicas y Procedimientos Especiales, SC

    Morelia, Michoacán, 58249, Mexico

  • Clinical Research Puerto Rico

    San Juan, 00909, Puerto Rico

  • Cliniques universitaires Saint-Luc

    Brussels, Bruxelles-capitale, Région de, 1200, Belgium

  • Clínica Gaias - Santiago

    Santiago de Compostela, Galicia [galicia], 15702, Spain

  • Clínica Gaias - Santiago

    Santiago de Compostela, 15702, Spain

  • Columbia Dermatology & Aesthetics

    Columbia, South Carolina, 29212, United States

  • Complete Dermatology

    Sugar Land, Texas, 77479, United States

  • Cri Centro Regiomontano de Investigacion

    Monterrey, Nuevo León, 64060, Mexico

  • Cura Clinical Research - Oxnard

    Oxnard, California, 93030, United States

  • DERMA-B Egészségügyi és Szolgáltató

    Debrecen, 4031, Hungary

  • DJL Clinical Research, PLLC

    Charlotte, North Carolina, 28211, United States

  • Darst Dermatology

    Charlotte, North Carolina, 28277, United States

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana, 46250, United States

  • Debreceni Egyetem Klinikai Kozpont

    Debrecen, 4032, Hungary

  • Derm-Surg Egészségügyi Szolgáltató és Tanácsadó Kft.

    Kaposvár, 7400, Hungary

  • DermEdge Research

    Mississauga, Ontario, L4Y 4C5, Canada

  • DermEffects

    London, Ontario, N6H 5L5, Canada

  • DermResearchCenter of New York, Inc.

    Stony Brook, New York, 11790, United States

  • Derma therapy spol. s.r.o.

    Bratislava, 851 01, Slovakia

  • Dermatology Associates of Plymouth Meeting

    Plymouth Meeting, Pennsylvania, 19462, United States

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, 510091, China

  • Dermatology Research Institute

    Calgary, Alberta, T2J 7E1, Canada

  • Dermatology Trial Associates

    Bryant, Arkansas, 72022, United States

  • Dermatology and Skin Cancer Specialists, LLC

    Rockville, Maryland, 20850, United States

  • Dermatology on Bloor - Research Toronto

    Toronto, Ontario, M4W 2N4, Canada

  • Diagnostic - Consultative Center XXVIII - Sofia

    Sofia, 1528, Bulgaria

  • Diagnostic Consultative Center "Ascendent"

    Sofia, 1202, Bulgaria

  • Diagnostic Consultative Center 1 - Pernik

    Pernik, 2300, Bulgaria

  • Diagnostic Consultative Center Aleksandrovska

    Sofia, Sofia (stolitsa), 1431, Bulgaria

  • Diagnostic Consultative Centre (DCC) - Foкus 5

    Sofia, Sofia (stolitsa), 1463, Bulgaria

  • Diex Recherche Quebec

    Québec, G1V 4T3, Canada

  • Diex Recherche Sherbrooke

    Sherbrooke, Quebec, J1L 0H8, Canada

  • Direct Helpers Research Center

    Hialeah, Florida, 33012, United States

  • Dr Rodney Sinclair Pty Ltd

    East Melbourne, Victoria, 3002, Australia

  • ETG Warszawa

    Warsaw, Masovian Voivodeship, 02-677, Poland

  • Encore Medical Research of Boynton Beach

    Boynton Beach, Florida, 33436, United States

  • Endeavor Health Audiology -CHICAGO

    Chicago, Illinois, 60625, United States

  • Endeavor Health Audiology -LAKE BLUFF

    Lake Bluff, Illinois, 60044, United States

  • Endeavor Health Audiology-NORTHBROOK

    Northbrook, Illinois, 60062, United States

  • Endeavor Health Audiology-SKOKIE

    Skokie, Illinois, 60076, United States

  • Endeavor Health-Dermatology Clinical Trials Unit

    Skokie, Illinois, 60077, United States

  • Eurofins Cosmetics CRL LLC

    Forest, Virginia, 24551, United States

  • FXM Clinical Research - Fort Lauderdale

    Fort Lauderdale, Florida, 33308, United States

  • FXM Clinical Research - Miami

    Miami, Florida, 33175, United States

  • FXM Clinical Research - Miramar

    Miramar, Florida, 33027, United States

  • Fakultna nemocnica Trnava

    Trnava, Trnava Region, 917 02, Slovakia

  • Fakultna nemocnica s poliklinikou F.D.Roosevelta Banska Bystrica

    Banská Bystrica, Banská Bystrica Region, 97517, Slovakia

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, 650032, China

  • First OC Dermatology Research Inc

    Fountain Valley, California, 92708, United States

  • Floridian Research Institute Llc

    Miami, Florida, 33179, United States

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, 20122, Italy

  • Fremantle Dermatology

    Fremantle, Western Australia, 6160, Australia

  • GCP Research, Global Clinical professionals

    St. Petersburg, Florida, 33714, United States

  • Gazi University Health Research and Application Center Gazi Hospital

    Ankara, 06560, Turkey (Türkiye)

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, 510180, China

  • Guy's & St Thomas' NHS Foundation Trust

    London, London, CITY of, SE1 9RT, United Kingdom

  • HNO-Praxis Dr. Kugler in Magdeburg

    Magdeburg, Saxony-Anhalt, 39104, Germany

  • Hamamatsu University Hospital

    Hamamatsu, Shizuoka, 431-3192, Japan

  • Hangzhou Third Hospital

    Hangzhou, Zhejiang, 310009, China

  • Hautarztpraxis Dr. Beatrice Gerlach

    Dresden, Saxony, 01097, Germany

  • Hautarztpraxis Dr. Neubauer

    Leipzig, Saxony, 04207, Germany

  • Hautzentrum im Jahrhunderthaus

    Bochum, North Rhine-Westphalia, 44793, Germany

  • Health and Life Research Institute

    Miami, Florida, 33176, United States

  • Henry Ford Medical Center - New Center One

    Detroit, Michigan, 48202, United States

  • Hospital Germans Trias i Pujol

    Badalona, Barcelona [barcelona], 08916, Spain

  • Hospital Universitari de Bellvitge

    L'Hospitalet de Llobregat, Barcelona [barcelona], 08907, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, 46026, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Infanta Leonor

    Madrid, Madrid, Comunidad de, 28031, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, 50009, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Andalusia, 14004, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 08041, Spain

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, 200040, China

  • IRCCS Istituti Fisioterapici Ospitalieri

    Roma, RM, 00144, Italy

  • Innovaderm Research Inc.

    Montreal, Quebec, H2X 2V1, Canada

  • Institute for Skin, Health and Immunity

    Mitcham, Victoria, 3132, Australia

  • Institute of Science Tokyo Hospital

    Bunkyo-ku, Tokyo, 113-8519, Japan

  • Integrative Skin Science and Research

    Sacramento, California, 95815, United States

  • Istituto Dermopatico Immacolata

    Rome, ROMA, 00167, Italy

  • JRB Research Inc.

    Ottawa, Ontario, K1K 4L2, Canada

  • Japan Community Health Care Organization Chukyo Hospital

    Nagoya, Aichi-ken, 457-8510, Japan

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210029, China

  • Juntendo University Urayasu Hospital

    Urayasu, Chiba, 279-0021, Japan

  • Kaiser Permanente

    Oakland, California, 94611, United States

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, 833401, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, 80756, Taiwan

  • Kindai University Nara Hospital

    Ikoma, Nara, 630-0293, Japan

  • Klinika Ambroziak Dermatologia

    Warsaw, Masovian Voivodeship, 02-953, Poland

  • Klinikum Bielefeld Rosenhöhe

    Bielefeld, North Rhine-Westphalia, 33647, Germany

  • Klinikum Bielefeld gem. GmbH

    Bielefeld, North Rhine-Westphalia, 33647, Germany

  • Krakowskie Centrum Medyczne

    Krakow, Lesser Poland Voivodeship, 31-501, Poland

  • MHAT Pazardzhik

    Pazardzhik, 4400, Bulgaria

  • Magdeburger Company for Medical Studies and Services

    Magdeburg, Saxony-Anhalt, 39104, Germany

  • MediSearch Clinical Trials

    Saint Joseph, Missouri, 64506, United States

  • Medical Center Exacta Medica

    Pleven, 5800, Bulgaria

  • Medical Center Prolet EOOD

    Rousse, 7000, Bulgaria

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Medicor Research Inc

    Greater Sudbury, Ontario, P3C 1X3, Canada

  • Miami Dermatology and Laser Institute

    Miami, Florida, 33133, United States

  • Mission Dermatology Center

    Rancho Santa Margarita, California, 92688, United States

  • Multiprofile Hospital for Active Treatment Sv. Panteleymon - Yambol AD

    Yambol, 8600, Bulgaria

  • NanYang First people's hospital

    Nanyang, Henan, 473000, China

  • National Taiwan University Hospital

    Taipei, 100225, Taiwan

  • New Horizon Research Center

    Miami, Florida, 33165, United States

  • North Eastern Health Specialists

    Campbelltown, South Australia, 5074, Australia

  • North York Research Inc

    Toronto, Ontario, M2N 3A6, Canada

  • Oakland Hills Dermatology

    Auburn Hills, Michigan, 48326, United States

  • OptiSkin Medical

    New York, New York, 10128, United States

  • Oregon Dermatology and Research Center

    Portland, Oregon, 97210, United States

  • Orvostudomanyi Kutato es Fejleszto Kft

    Debrecen, 4027, Hungary

  • Osaka Habikino Medical Center

    Habikino, Osaka, 583-8588, Japan

  • Ospedale Civile - Azienda Ospedaliera Universitaria di Cagliari

    Cagliari, 09124, Italy

  • Ospedale Israelitico

    Rome, ROMA, 00148, Italy

  • Palmetto Clinical Trial Services - Greenville

    Greenville, South Carolina, 29615, United States

  • Paratus Clinical Research Woden

    Phillip, Australian Capital Territory, 2606, Australia

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

  • Peninsula Research Associates

    Rolling Hills Estates, California, 90274, United States

  • Physician Research Collaboration, LLC

    Lincoln, Nebraska, 68516, United States

  • Poliklinika ProCare Kosice s.r.o.

    Košice, 040 23, Slovakia

  • Presidio Ospedaliero Firenze Centro Piero Palagi

    Florence, Firenze, 50125, Italy

  • Pécsi Tudományegyetem Klinikai Központ

    Pécs, Baranya, 7632, Hungary

  • Radiologie Ulrichshaus

    Magdeburg, Saxony-Anhalt, 39104, Germany

  • Rosenpark Research GmbH

    Darmstadt, Hesse, 64283, Germany

  • Royal North Shore Hospital

    St Leonards, New South Wales, 2065, Australia

  • Royalderm Agnieszka Nawrocka

    Warsaw, Masovian Voivodeship, 02-962, Poland

  • SANARE, s.r.o

    Svidník, Presov, 089 01, Slovakia

  • Sanitas Research

    Miami, Florida, 33186, United States

  • Saskatoon Dermatology Centre

    Saskatoon, Saskatchewan, S7T 0G3, Canada

  • Seaside Audiology Vertigo & Ear Specialists

    Huntington Beach, California, 92648, United States

  • Servicios Hospitalarios de Mexico S.A. DE C.V.

    Chihuahua City, 31238, Mexico

  • Shanghai General Hospital

    Shanghai, 200080, China

  • Sidney P. Smith, MD, PC dba Georgia Skin & Cancer Clinic

    Savannah, Georgia, 31419, United States

  • SimcoDerm Medical and Surgical Dermatology Center

    Barrie, Ontario, L4M 7G1, Canada

  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310016, China

  • Skin Research of South Florida

    Miami, Florida, 33173, United States

  • Skinsense Medical Research

    Saskatoon, Saskatchewan, S7K 2C1, Canada

  • SouthCoast Research Center

    Miami, Florida, 33136, United States

  • Southampton General Hospital

    Southampton, Hampshire, SO16 6YD, United Kingdom

  • Specderm Poznanska sp.j.

    Bialystok, Podlaskie Voivodeship, 15-375, Poland

  • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka

    Krakow, Lesser Poland Voivodeship, 30-002, Poland

  • Springville Dermatology - Springville/CCT Research

    Springville, Utah, 84663, United States

  • St George Dermatology & Skin Cancer Centre

    Kogarah, New South Wales, 2217, Australia

  • Sudbury Skin Clinique

    Greater Sudbury, Ontario, P3C 1X8, Canada

  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ

    Szeged, Csongrád megye, 6720, Hungary

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • Takarazuka City Hospital

    Takarazuka, Hyōgo, 665-0827, Japan

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, 550004, China

  • The Alfred Hospital

    Melbourne, Victoria, 3004, Australia

  • The Centre for Clinical Trials

    Oakville, Ontario, L6J 7W5, Canada

  • The First Affiliated Hospital Of Fujian Medical University

    Fuzhou, Fujian, 350005, China

  • The First Affiliated Hospital of Baotou Medical College

    Baotou, Inner Mongolia, 014010, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, 710061, China

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, 050030, China

  • The First Hospital of Jilin University

    Changchun, Jilin, 130021, China

  • The First Hospital of Wuhan

    Wuhan, Hubei, 430022, China

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, 5011, Australia

  • The Royal Melbourne Hospital

    Parkville, Victoria, 3050, Australia

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, 410011, China

  • The Skin Care Centre

    Vancouver, British Columbia, V5Z 4E8, Canada

  • The South Bend Clinic, LLC

    South Bend, Indiana, 46617, United States

  • The Woodlands Dermatology Associates, PA

    The Woodlands, Texas, 77380, United States

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, 300052, China

  • Toho University Sakura Medical Center

    Sakura, Chiba, 285-8741, Japan

  • Tokyo Medical University Ibaraki Medical Center

    Inashiki-gun, Ibaraki, 300-0395, Japan

  • Topskin pro s.r.o.

    Košice, 04001, Slovakia

  • Trial Pharma - Semper Medical Center

    Békéscsaba, 5600, Hungary

  • Trials in Medicine

    Mexico City, Mexico City, 06700, Mexico

  • Twoja Przychodnia SCM

    Szczecin, West Pomeranian Voivodeship, 71-500, Poland

  • UMHAT "Prof. Dr. Stoyan Kirkovich"AD

    Stara Zagora, 6003, Bulgaria

  • USF Health

    Tampa, Florida, 33612, United States

  • UZ Gent

    Ghent, Oost-vlaanderen, 9000, Belgium

  • UZ Leuven

    Leuven, Vlaams-brabant, 3000, Belgium

  • Universitaetsklinikum Carl Gustav Carus Dresden

    Dresden, 01307, Germany

  • University of California San Diego - La Jolla

    San Diego, California, 92122, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Miami Dermatology Clinical Trials Unit

    Miami, Florida, 33136, United States

  • University of Miami, Kendall Office

    Miami, Florida, 33176, United States

  • University of New Mexico Health Sciences Center

    Albuquerque, New Mexico, 87102, United States

  • University of Utah

    Murray, Utah, 84107, United States

  • Universitätsklinikum Bonn

    Bonn, North Rhine-Westphalia, 53127, Germany

  • Université Libre de Bruxelles - Hôpital Erasme

    Brussels, Bruxelles-capitale, Région de, 1070, Belgium

  • Veracity Clinical Research

    Woolloongabba, Queensland, 4102, Australia

  • Wallace Medical Group, Inc

    Los Angeles, California, 90056, United States

  • Wayne Health

    Detroit, Michigan, 48201, United States

  • Well Pharma Medical Research, Corp.

    Miami, Florida, 33173, United States

  • Wellness Clinical Research

    Miami Lakes, Florida, 33016, United States

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

  • West Middlesex University Hospital

    Isleworth, England, TW7 6AF, United Kingdom

  • Wiseman Dermatology Research Inc.

    Winnipeg, Manitoba, R3M 3Z4, Canada

  • Wolverine Clinical Trials

    Santa Ana, California, 92706, United States

  • Yamaguchi University Hospital

    Ube, Yamaguchi, 755-8505, Japan

  • York Dermatology Clinic & Research Centre

    Richmond Hill, Ontario, L4B 1L1, Canada

  • Óbudai Egészségügyi Centrum

    Budapest, 1036, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.